Vilket är priset för Philogen S.p.A. (PHIL)

Priset för Philogen S.p.A. (PHIL) är $27.76

Vilket är marknadsvärdet för Philogen S.p.A. (PHIL)

Marknadsvärdet för Philogen S.p.A. (PHIL) är $801.60M

Philogen S.p.A. (PHIL) Rörelsemarginal

Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.

År	Rörelsemarginal	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Rörelsemarginal

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Rörelsemarginal	Skillnad i rörelsemarginal	Land
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.72%	-	AU
Moderna, Inc. MRNA.US	-149.01%	-	US
Lonza Group AG LONN.SW	0.00%	-	CH

Företag

Rörelsemarginal

Skillnad i rörelsemarginal

Land